A recent systematic review found that for patients who underwent pelvic organ prolapse (POP) surgery, pain with sex decreased and overall sexual function improved or was unchanged. The results may inform how surgeons discuss POP surgery with patients.
Initial results from the Southwest Oncology Group (SWOG) phase 3 RxPONDER trial demonstrate that postmenopausal women with a common form of breast cancer may be able to forego chemotherapy — and its potential adverse effects — in favor of standalone hormone therapy.
New guidelines on how to treat hereditary breast cancer could be a gamechanger.
Convenience, fewer missed appointments and lower insurance costs benefit patients and doctors. Having access to patients’ medical records, private on-camera communication, and reducing unnecessary in-office and ER visits are a few reasons telemedicine continues to grow in popularity.
Study Suggests Connection Between Ovarian Cancer and Fibrosis, Provides Possible Risk Management Option
A recent study in Ottawa poses a connection between ovarian fibrosis and the risk of developing ovarian cancer, and hints at a drug that may decrease that risk.
Researchers at the University of Washington and four other health institutes explore whether at-home screening tests are an efficient and effective way to detect cervical precancer.
By scrutinizing breast cancer cell lines, tissue grafts and samples, as well as data from The Cancer Genome Atlas, researchers at The Graduate Center of The City University of New York (CUNY) and Hunter College, along with colleagues at Memorial Sloan Kettering Cancer Center and The...
New research pushes back against suggestions that screening mammography may no longer be a primary factor in decreased breast cancer mortality.
In the final results of a major international clinical trial, women with hormone receptor-negative breast cancer who received a combination of standard chemotherapy and hormone treatment were more likely to become pregnant and enjoyed a better five-year survival rate than patients who received chemotherapy alone.
Research presented at a meeting of the Radiological Society of North America (RSNA) adds to existing evidence that women age 75 or older benefit from continued mammography screening, expanding the debate about whether the age recommendations for these screenings should change.
- 1 of 5
- next ›